Lidocaine - NEMO consortium/Only for Children Pharmaceuticals

Drug Profile

Lidocaine - NEMO consortium/Only for Children Pharmaceuticals

Latest Information Update: 09 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NEMO Consortium; Only for Children Pharmaceuticals
  • Developer Only for Children Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neonatal seizures

Most Recent Events

  • 09 May 2016 Chemical structure information added
  • 31 Mar 2015 Preclinical trials in Neonatal seizures in France (unspecified route) before March 2015
  • 01 Feb 2015 NEMO Consortium submits Paediatric Investigation Plan to EMA for Neonatal seizures
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top